- ConcertAI and NVIDIA collaborate to advance translational and clinical development solutions within the ConcertAI CARA AI platform.
- ConcertAI has curated the most extensive multi-modal oncology data repository in the industry, exceeding 8 million patients.
- Key initiatives include high-performance AI models for clinical development solutions, large-scale processing of multi-modal data, and the development of precision oncology and medical large language models (LLMs).
- The collaboration aims to enhance AI-driven insights in oncology research, clinical development, and care, ultimately improving outcomes for patients with unmet medical needs.
- NVIDIA’s expertise and infrastructure in AI complement ConcertAI’s efforts, propelling innovation in clinical trial design and outcome prediction.
Main AI News:
ConcertAI, a trailblazing company in oncology real-world evidence data and AI SaaS technology, has announced a strategic collaboration with NVIDIA aimed at advancing a diverse range of translational and clinical development solutions within the ConcertAI CARA AI platform. Leveraging NVIDIA’s cutting-edge Inference microservices (NIM) and CUDA-X microservices, along with the powerful NVIDIA NeMo platform, this collaboration represents a significant leap forward in the realm of oncology research and treatment.
In the past couple of years, ConcertAI has curated the most comprehensive multi-modal oncology data repository in the industry, boasting a staggering database of over 8 million patients. This endeavor was accelerated notably in December 2023 when the American Society of Clinical Oncology (ASCO) CancerLinQ program merged with ConcertAI under a long-term cooperation agreement. Through collaborative efforts with molecular diagnostic partners and TeraRecon, its radiological imaging business, ConcertAI has established a research capability that encompasses genomic, transcriptomic, digital pathology, digital radiology, clinical, and social determinants of health data. This vast dataset spans all 50 states, offering unparalleled representativeness and generalizability, laying the groundwork for the development of next-generation AI models and AI-powered services. In January, the company unveiled its CARA AI platform, heralding a new era of AI SaaS solutions underpinned by its multi-modal data solutions, catering to healthcare providers, research sites, and life science companies.
In alignment with this collaboration, ConcertAI’s pursuit of cutting-edge intelligence and insights in oncology research and treatment will be bolstered by NVIDIA’s expertise and infrastructure in AI. The integration of Meta Llama 3 NIM, introduced at Computex, will play a pivotal role in driving critical LLM workloads within ConcertAI’s suite of solutions. The partnership will focus on enhancing large-scale clinical data processing, multi-agent models, clinical foundation models, and related solutions, facilitating the seamless interoperability of domain-specific AI and broad application generative AI with unprecedented precision.
Key initiatives stemming from this collaboration include:
- High-performance AI models for clinical development solutions: Leveraging NVIDIA NIMs to facilitate scalable, high-performance AI model deployment with minimal latency, thereby enhancing flexibility, interoperability, and cost efficiency within the ConcertAI CARA AI platform. This integration will bolster clinical trial patient matching, protocol automation, and research site co-pilots with real-time analytics and model management for large-scale AI applications.
- Large-scale processing of multi-modal data: Harnessing NVIDIA CUDA-X microservices to accelerate ConcertAI’s large-scale data processing pipelines, thus augmenting the world’s largest curated oncology dataset. By leveraging CUDA-X’s advanced computing capabilities, ConcertAI aims to achieve swifter data processing speeds and improved efficiency, facilitating more effective management of its expansive oncology data.
- Development of precision oncology and medical large language models (LLMs): These foundational models, trained on ConcertAI’s industry-leading multi-modal data, will underpin advanced translational simulations aimed at guiding novel, first-in-human studies, optimizing clinical trial designs, providing clinical decision augmentation support, and identifying beneficial diagnostic and treatment approaches.
Jeff Elton, PhD, CEO of ConcertAI, emphasized, “Life sciences research and precision medicine both involve complex decisions based on vast amounts of data and time points. AI has the potential to unlock insights that were previously unattainable with traditional methods. We are excited to collaborate with NVIDIA to push the boundaries of AI in oncology translational research, clinical development, and care, ultimately accelerating the advancement of outcomes for patients with significant unmet medical needs.“
Kimberly Powell, VP of Healthcare at NVIDIA, commented, “AI holds immense promise in revolutionizing the design and development of medicines, and integrating generative AI tools to enhance clinical trials represents a groundbreaking step forward. The integration of NVIDIA’s NIMs into ConcertAI’s SaaS platform and extensive multi-modal data infrastructure will transform clinical trial design and outcome prediction, marking a significant advancement in healthcare.”
Conclusion:
The collaboration between ConcertAI and NVIDIA signifies a significant advancement in the oncology research and healthcare market. By leveraging cutting-edge AI technologies and vast datasets, they aim to revolutionize clinical development processes, driving efficiency, and precision in oncology research and treatment. This partnership underscores the growing importance of AI in transforming healthcare and underscores a shift towards data-driven approaches in oncology.
